Ingrezza Sprinkle — Medical Mutual
Tardive Dyskinesia (TD) - Continuing Therapy
Reauthorization criteria
- Patient is age ≥ 18 years; AND
- Ingrezza is prescribed by or in consultation with a neurologist or psychiatrist; AND
- Patient has experienced improvement in, or maintenance of, symptoms while on the requested medication
Approval duration
1 year